Guidelines for dyslipemias treatment: Adult Treatment Panel III (ATP-III);Guías para el tratamiento de las dislipemies en el adulto: Adult Treatment Panel III (ATP-III)

Endocrinologia y Nutricion

Volumn 51, Issue 5, 2004, Pages 254-265

  Rubio, M A ^a   Moreno, C ^a   Cabrerizo, L ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

ATP III; Cardiovascular risk factors; Dyslipemias; Elevated triglycerides

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; STATINE DERIVATIVE; TRIACYLGLYCEROL;

ALGORITHM; ATHEROGENIC DIET; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; EDUCATION PROGRAM; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; OBESITY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; SITTING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 3042773331     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1575-0922(04)74614-8     Document Type: Article

References (78)

1. Villar F, Banegas JR, Donado JM, Rodríguez-Artalejo F. Las enfermedades cardiovasculares y sus factores de riesgo en España: hechos y cifras. Informe SEA 2003. Madrid: Ergon, 2003.
2. Marrugat J, Elosua R, Martí H. Epidemiología de la cardiopatía isquémica en España: estimación del número de casos y las tendencias entre 1997 y 2005. Rev Esp Cardiol 2002;55:337-46.
3. Executive Summary of the third report of the Nacional Colesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Colesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
4. Executive Summary of the third report of the Nacional Colesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Colesterol in Adults (Adult Treatment Panel III): final report. US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Heart, Lung, Blood Institute. Circulation 2002;106:3143-420.
5. International Atherosclerosis Society y Sociedad Española de Arteriosclerosis. Guías clínicas armonizadas para la prevención de la enfermedad vascular aterosclerótica. Barcelona: Medical Trends S.L. editores, 2003 [documento íntegro disponible en: http://www.searteriosclerosis.org].
6. Ernst ND, Cleeman JI. National cholesterol education program keeps a priority on lifestyle modification to decrease cardiovascular disease risk. Curr Opin Lipidol 2002;13:69-73.
7. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(Suppl 4A):7B-12B.
8. Assman G, Schulte H, Funke H, Von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19(Suppl M):8-14.
9. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998;81:13B-7B.
10. Seman LJ, DeLuca C, Jenner JL, Cupples LA, McNamara JR, Wilson PW, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem 1999;45:1039-46.
11. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-5.
12. Moliterno DJ, Jokinen EV, Miserez AR, Lange RA, Willard JE, Boerwinkle E, et al. No association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis in African-Americans. Arterioscler Thromb Vasc Biol 1995;15:850-5.
13. Tornvall P, Bavenholm P, Landou C, De Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation 1993;88:2180-9.
14. Montalescot G, Collet JP, Choussat R, Thomas D. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998;19(Suppl H):11-7.
15. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, De Faire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEP) study. Arterioscler Thromb Vasc Biol 2000;20:2019-23.
16. Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, et al. Thrombogenic factors and recurrent coronary events. Circulation 1999;99:2517-22.
17. Hackman DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease. A critical review of evidence. JAMA 2003;290:932-40.
18. Heeschen C, Dimmeler S, Hamm CW, Van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104-11.
19. Varo N, De Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation 2003;108:1049-52.
20. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
21. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts furture risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984 to 1992. Circulation 1999;99:237-42.
22. Grundy SM, Denke MA. Dietary influences on serum lipids and lipoproteins. J Lipid Res 1990;31:1149-72.
23. Mensink RP, Katan MB. Effects of dietary fatty acids on serum lipids and lipoproteins: a meta-analysis of 27 trials. Arterioescler Thromb 1991;12:911-9.
24. Kris-Etherton PM, Yu S. Individual fatty acids effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr 1997;65(Suppl):1628S-44S.
25. Ros E. El colesterol de la dieta y su escasa influencia sobre la colesterolemia y el riesgo cardiovascular. Clin Invest Arterioscler 2000;12(Supl 2):20-6.
26. Lichtenstein AH, Ausman LM, Jalbert SM, Schaefer EJ. Effects of different forms of dietary hydrogenated fats on serum lipoprotein cholesterol levels. N Engl J Med 1999;340:1933-40.
27. Ascherio A, Katan MB, Zock PL, Stampfer MJ, Willet WC. Trans fatty acid and coronary heart disease. N Engl J Med 1999;340:1994-8.
28. Feldman E. Assorted monounsaturated fatty acids promote healthy hearts. Am J Clin Nutr 1999;70:953-4.
29. Ascherio A, Rimm EB, Stampfer MJ, Giovanucci El, Willet WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. N Engl J Med 1995;332:977-82.
30. Fraser GE. Nut consumption, lipids and risk of a coronary event. Clin Cardiol 1999;22(Suppl 3):11-5.
31. De Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, Monjaud I, et al. Mediterranean alpha-linoleic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994 343:1454-9.
32. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-23.
33. Morris CD, Carson S. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the U.S. preventive services Task Force. Ann Intern Med 2003;139:56-70.
34. Venn BJ, Mann JI, Williams SM, Riddell LJ, Chisholm A, Harper MJ, et al. Dietary counseling to increase natural folate intake: a randomized, placebo-controlled trial in free-living subjects to assess effects on serum folate and plasma total homocysteine. Am J Clin Nutr 2002;76:758-65.
35. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-8.
36. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults -the evidence report. Obes Res 1998;6(Suppl 2):51-209.
37. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97:2099-100.
38. Rajala MW, Scherer PE. The adipocyte at the cossroads of energy homoestasis, inflammation, and atherosclerosis. Endocrinology 2003;144:3765-73.
39. Lyon CJ, Law RE, Hsueh WA. Adiposity, inflammation and atherogenesis. Endocrinology 2003;144:2195-200.
40. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metabol 2004;89:447-52.
41. Fletcher GF, Balady G, Blair SN, Blumenthal J, Caspersen C, Chaitman B, et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 1996;94:857-62.
42. Thompson DA, Buchner D, Piña IL, Balady GJ, Williams MA, Marcus BH, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease. A statement from the Council on Clinical Cardiology (subcommittee on exercise, rehabilitation, and prevention) and the Council on Nutrition, Physical Activity, and Metabolism (subcommittee on physical activity). Circulation 2003;10703109-16.
43. Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004;109:433-8.
44. American Diabetes Association. Position statement. Implications of the diabetes control and complications trial. Diabetes Care 2002;25:S25-S7.
45. UK Prospective Diabetes Study (UDPDS) Group: intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
46. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34.
47. Leng GC, Fowkes FG, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996;313:1440-4.
48. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991;87:119-28.
49. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study: endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995;273:1421-8.
50. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
51. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-5.
52. Word D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998;140:199-270.
53. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol 2003;56:253-61.
54. Conroy RM, Pyörölä K, Fitzgerald S, Sans C, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the Score project. Eur Heart J 2003;24:987-1003.
55. Masana Martín L. Del Panel III en adelante. ¿Debemos basarnos en la evidencia científica o en la observación epidemiológica? Clin Invest Arterioscl 2003;15(Supl 3):54-61.
56. Heart Protection Study Collaborative Group. MRC/BHF heart protection study. Randomised placebo-controlled trial of cholesterol-lowering with simvastatin in 20,536 high-risk individuals. Lancet 2002;360:7-22.
57. Scandinavian Simvastatin Survival Study. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
58. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
59. Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
60. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
61. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Comparison of intensive and moderate lipid lowering with statins following acute coronary syndrome. N Engl J Med 2004;350:1495-504.
62. US Public Health Service. A clinical practice guideline for treating tobacco use and dependence: a US Public Health Service report. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. JAMA 2000;283:3244-54.
63. Joint National Committee. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
64. World Health Organization. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
65. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581-3.
66. Gómez Gerique JA y grupo DRECE. Impacto farmacoeconómico de las directrices del ATP-III. Clin Invest Arterioscl 2003;15(Supl 3):17-33.
67. National Institutes of Health: National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol (Adult Treatment Panel II). Circulation 1994;89:1333-445.
68. Plat J, Kerckhoffs D, Mensink RP. Therapeutical potential of plant sterols and stanols. Curr Opin Lipidol 2000;11:571-6.
69. Law M. Plant sterol and stanol margarines and health. BMJ 2000;320:861-4.
70. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30-42.
71. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, et al. AHA dietary guidelines: revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000;102:2284-99.
72. Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr 2002;76:93-9.
73. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation 1999;99:779-85.
74. Kris-Etherton PM, Harris WS, Appel LJ, for the Nutrition Committee Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease. Arterioscler Thromb Vasc Biol 2003;23:e20-e31.
75. Guallar E, Aro A, Jiménez FJ, Martín-Moreno JM, Salminen I, Van't Veer P, et al. Omega-3 fatty acids in adipose tissue and risk of myocardial infarction. The EURAMIC study. Arterioscler Thromb Vasc Biol 1999;19:1111-8.
76. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willet WC, et al. Fish consumptionn and risk of sudden cardiac death. JAMA 1998;279:23-8.
77. Geelen A, Brouwer IA, Zock PL, Katan MB. Antiarrhythmic effects of n-3 fatty acids: evidence from human studies. Curr Opin Lipidol 2004;15:25-30.
78. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA, Stampfer MJ, Willett WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003;348:109-18.